Abstract:Zonulin protein is a newly discovered modulator which modulates the permeability of the intestinal epithelial barrier by disassembling intercellular tight junctions (TJ). Disruption of TJ is associated with neonatal necrotizing enterocolitis (NEC). It has been shown bifidobacterium could protect the intestinal barrier function and prophylactical administration of bifidobacterium has beneficial effects in NEC patients and animals. However, it is still unknown whether the zonulin is involved in the gut barrier dysfunction of NEC, and the protective mechanisms of bifidobacterium on intestinal barrier function are also not well understood. The present study aims to investigate the effects of bifidobacterium on intestinal barrier function, zonulin regulation, and TJ integrity both in LPS-induced enterocyte barrier injury of Caco-2 monolayers and in a rat NEC model. Our results showed bifidobacterium markedly attenuated the decrease in transepithelial electrical resistance and the increase in paracellular permeability in the Caco-2 monolayers treated with LPS (P < 0.01). Compared with the LPS group, bifidobacterium significantly decreased the production of IL-6 and TNF-α (P < 0.01) and suppressed zonulin release (P < 0.05). In addition, bifidobacterium pretreatment up-regulated occludin, claudin-3 and ZO-1 expression (P < 0.01) and also preserved these proteins localization at TJ compared with the LPS group. In the in vivo study, bifidobacterium decreased the incidence of NEC from 88 to 47% (P < 0.05) and reduced the severity in the NEC model. Increased levels of IL-6 and TNF-α in the ileum of NEC rats were normalized in bifidobacterium treated rats (P < 0.05). Moreover, administration of bifidobacterium attenuated the increase in intestinal permeability (P < 0.01), decreased the levels of serum zonulin (P < 0.05), normalized the expression and localization of TJ proteins in the ileum compared with animals with NEC. We concluded that bifidobacterium may protect against intestinal barrier dysfunction both in vitro and in NEC. This protective effect is associated with inhibition of proinflammatory cytokine secretion, suppression of zonulin protein release and improvement of intestinal TJ integrity.

Cathelicidin-BF Ameliorates Lipopolysaccharide-Induced Intestinal Epithelial Barrier Disruption in Rat.

Antimicrobial Peptide Cathelicidin-BF Prevents Intestinal Barrier Dysfunction in a Mouse Model of Endotoxemia.

Cathelicidin-BF suppresses intestinal inflammation by inhibiting the nuclear factor-κB signaling pathway and enhancing the phagocytosis of immune cells via STAT-1 in weanling piglets

Cathelicidin-BF, a Novel Antimicrobial Peptide from Bungarus fasciatus, Attenuates Disease in a Dextran Sulfate Sodium Model of Colitis

Effects of Cathelicidin-Derived Peptide from Reptiles on Lipopolysaccharide-Induced Intestinal Inflammation in Weaned Piglets.

Lactobacillus rhamnosus CY12 Enhances Intestinal Barrier Function by Regulating Tight Junction Protein Expression, Oxidative Stress, and Inflammation Response in Lipopolysaccharide-Induced Caco-2 Cells

L-Cysteine Protects Intestinal Integrity, Attenuates Intestinal Inflammation And Oxidant Stress, And Modulates Nf-B And Nrf2 Pathways In Weaned Piglets After Lps Challenge

Cecropin A Modulates Tight Junction-Related Protein Expression and Enhances the Barrier Function of Porcine Intestinal Epithelial Cells by Suppressing the MEK/ERK Pathway

Cathelicidin-WA Improves Intestinal Epithelial Barrier Function and Enhances Host Defense against Enterohemorrhagic Escherichia coli O157:H7 Infection

Cathelicidin-WA Facilitated Intestinal Fatty Acid Absorption Through Enhancing PPAR-γ Dependent Barrier Function

Protective Effects of Bifidobacterium on Intestinal Barrier Function in LPS-Induced Enterocyte Barrier Injury of Caco-2 Monolayers and in a Rat NEC Model

Clostridium Tyrobutyricum Protect Intestinal Barrier Function from LPS-Induced Apoptosis Via P38/JNK Signaling Pathway in IPEC-J2 Cells

Cathelicidin-WA attenuates LPS-induced inflammation and redox imbalance through activation of AMPK signaling.

Cathelicidin-WA Protects Against LPS-Induced Gut Damage Through Enhancing Survival and Function of Intestinal Stem Cells.

Lactoferrin Attenuates Lipopolysaccharide-Stimulated Inflammatory Responses and Barrier Impairment Through the Modulation of NF-κB/MAPK/Nrf2 Pathways in IPEC-J2 Cells.

Caprylic Acid and Nonanoic Acid Upregulate Endogenous Host Defense Peptides to Enhance Intestinal Epithelial Immunological Barrier Function Via Histone Deacetylase Inhibition

Porcine Β-Defensin 2 Attenuates Inflammation and Mucosal Lesions in Dextran Sodium Sulfate–Induced Colitis

Cbp22, A Novel Bacteriocin Isolated From Clostridium Butyricum Zju-F1, Protects Against Lps-Induced Intestinal Injury Through Maintaining The Tight Junction Complex

Porcine Lactoferrin-Derived Peptide LFP-20 Protects Intestinal Barrier by Maintaining Tight Junction Complex and Modulating Inflammatory Response.

L-Arginine Ameliorates Lipopolysaccharide-Induced Intestinal Inflammation Through Inhibiting the TLR4/NF-κB and MAPK Pathways and Stimulating Β-Defensin Expression in Vivo and in Vitro.

Paeoniflorin Prevents Intestinal Barrier Disruption and Inhibits Lipopolysaccharide (LPS)-Induced Inflammation in Caco-2 Cell Monolayers